Many studies demonstrate that conventional anticancer drugs elevate intracellular level of reactive oxygen species (ROS) and alter redox-homeostasis of cancer cells. It is widely accepted that anticancer effect of these chemotherapeutics is due to induction of oxidative stress and ROS-mediated apoptosis in cancer. On the other hand, the harmful side effects of conventional anticancer chemotherapy are also due to increased production of ROS and disruption of redox-homeostasis of normal cells and tissues. This article describes the mechanisms for triggering and modulation of apoptosis through ROS-dependent and ROS-independent pathways. We try to answer the question: "Is it possible to induce highly specific apoptosis only in cancer cells, without overproduction of ROS, as well as without harmful effects on normal cells and tissues?" The review also suggests a new therapeutic strategy for selective killing of cancer cells, without significant impact on viability of normal cells and tissues, by combining anticancer drugs with redox-modulators, affecting specific signaling pathways and avoiding oxidative stress.
induction of mitogenic response (16, (21) (22) (23) . Increased intracellular levels of ROS could stimulate signal pathways, and are responsible for cell proliferation (16, 21, 22, (24) (25) (26) (27) (28) , apoptosis (16, 22, (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) or activation of adaptive mechanisms through stimulation of antioxidant systems (4, (16) (17) (18) 21, 22, 24, (37) (38) (39) . There are convincing evidences that low/moderate levels of ROS could activate kinases and/ or inhibit phosphatases, which affect the activities of many enzymes (38, 39) . The most common mechanism of these regulatory processes is the interaction of ROS with cysteine residues and formation of disulfide bonds, with subsequent activation of signal-transduction pathways (24, 35, 36, (38) (39) (40) .
In contrast, overproduction of ROS above permissible levels could result in damage of the cellular macromolecules and supramolecular complexes (e.g., biomembranes) or activation of specific signaling pathways, leading to uncontrolled cell proliferation. These processes are associated with pathogenesis of different diseases, especially cancers (1, 2, 5, 8, 11, 17, 18, 21, 22, 24, 25, (27) (28) (29) (41) (42) (43) . There is a hypothesis that ROS have a key role in carcinogenesis by inducing and maintaining oncogenic phenotypes in cancer cells (18, 22, 24, 36, 38, (40) (41) (42) (43) (44) . ROS participate in the multistage carcinogenesis from initiation to malignant conversion by causing oxidative DNA damages and mutations in proto-oncogenes and tumor suppressor genes, as well as subsequent activation of signal transduction pathways (24, 38) . Superoxide is considered as a main candidate among all types of ROS, which is responsible for genetic instability and malignant transformation.
Many studies suggest that cancer cells usually have an increased level of ROS, as well as over-expression of antioxidant enzymes in response to the permanent oxidative stress, in comparison with normal cells (18, 22, 24, 36, 38, (40) (41) (42) (43) (44) . For example, Szatrowski et al. have shown that various human cancer cell lines, isolated from different tissue types, produce large amounts of hydrogen peroxide (45) . Weinberg et al. have reported that defects in the manganese-dependent superoxide dismutase (Mn-SOD) induce overproduction of superoxide and cause permanent expression of cyclin D1 gene and disregulation of mitogenactivated protein kinase (MAPK) signaling pathway (10) . The authors suggest that enhanced generation of ROS by cancer cells is responsible for the enhancement of their malignant (neoplastic) behavior -increasing of genomic instability and penetration into the host-tissues.
Recently, it has been found that various ROS-modulated molecular targets (signal molecules) activate different signaling pathways in the cells and could be considered as potential candidates for triggering carcinogenesis, metastasis and resistance to anticancer therapy. ROS contribute to the activation (up-regulation) of mammalian target of rapamycin (mTOR), a member of phosphoinositide 3-kinase (PI3K)-signaling pathway, which is associated with induction of malignant transformation (25, 27, 28, 46) . mTOR participates in energy sensing and is a key regulator of protein synthesis, a stimulator of cell growth and proliferation. Ras proteins, which are membrane-bound G proteins with the main function of regulating cell growth and opposing apoptotic effects, are also activated by ROS and ROSgenerating factors (e.g., ultraviolet irradiation, transition metals, mitogenic stimuli). It was found that the Ras gene is mutated in 30% of cancers of the lung, skin, liver, bladder and colon (47, 48) . ROS cause directly mutations in tumor suppressor protein p53 (49) . Mutation of p53 or loss of its function is observed in over 50% of human cancers, especially in cancers at advanced stages (50) . p53 has a crucial role in sensing and removing oxidative damages of nuclear and mitochondrial DNA, preventing oxidative gene mutations and genetic instability. p53 is activated by ultraviolet irradiation, hypoxia, gamma-irradiation, and other ROS-generating factors. Several cysteine residues in central domain of p53 protein are critical for its binding to the specific DNA sequence. Since the reduction of disulphide bonds or oxidation of sulfhydryl groups often occurs at a post-translational level, p53 is considered as one of the oxidative stress response transcription factors (16) . ROS induce release of calcium from intracellular stores, resulting in activation of kinases, such as protein kinases C (PK-C), which is a member of serine/threonine kinases (16) . PK-C contains several cysteine-rich regions both in the zinc finger of the regulatory domain and in the catalytic site, which can be modified by various oxidants (51) . One of the possible mechanisms of PK-C activation is tyrosine phosphorylation and conversion to the Ca 2+ /phospholipidindependent form. It seems that oxidant-induced PK-C activation plays a crucial role in cell proliferation (16, 52) . It has been reported that ROS promote expression of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κ B) and activator protein 1 (AP-1) -transcription factors, that also control cytokine production and cell survival (53) (54) (55) . The mechanisms of ROS-mediated expression of the transcription factors are not clear yet, but studies indicate that ROS, serve as secondary messengers, are involved in the activation of NF-κB via tumor necrosis factor (TNF) and interleukin-1 (IL-1) (56) . The activation of NF-κB can be blocked by antioxidants, such as L-cysteine, N-acetyl-cysteine (NAC), other thiols, polyphenols and Vitamin E (16) . Some studies demonstrate that ROS stimulate cancer cells to secrete matrix metalloproteinases (MMPs), which leads to vascular growth within the tumor microenvironment (angiogenesis) and increases the risk of blood-borne metastases (57, 58) . This process is associated with ROS-mediated activation of NF-κB and AP-1 and their binding to cysteine-rich sites in the promoter regions of the MMP-2, MMP-9 and MMP-12 genes (53,59). All molecular mechanisms described above, as well as many other mechanisms could trigger simultaneously two opposite events -uncontrolled cell proliferation or permanent cell cycle arrest. This is the most impressive fact in these signaling pathways -any signal, for example, intracellular overproduction of ROS can induce two opposite effects: 1) activation of proliferative signaling pathways and cell survival; or 2) activation of the apoptotic signaling pathways and cell death. This phenomenon is usually explained by the different amounts of ROS. It is widely accepted that the low levels of ROS activate cell proliferation, survival and viability, which are accompanied by genetic instability -a basis of carcinogenesis. The high levels of ROS are associated with apoptosis.
There are also other opinions about the main switch between proliferation and apoptosis, but the aim of this review is to focus on one matter with practical importance -how to induce highly specific apoptosis only in cancer cells, without overproduction of ROS and harmful effects on normal cells and tissues?
ROS and involvement of redox-status in apoptosis
A large number of studies demonstrate the relationship between the increased intracellular levels of ROS and induction of apoptosis in the cells (60-65). As it was described above, the mechanisms of induction of apoptosis by most of the conventional anticancer drugs have been associated with enhanced levels of ROS and/or decreased activity of antioxidant enzymes, which is accompanied by changes in cellular redox-homeostasis (20, 29, (66) (67) (68) (69) (70) (71) (72) (73) (74) . This observation suggests that increasing ROS and changing cellular redox-homeostasis could be part of a signal pathway, which induces apoptosis (65) .
Apoptosis is a form of programmed cell death, which physiologically plays a role in embryogenesis, metamorphosis, differentiation, proliferation, as a defense mechanism to remove infected, mutated or damaged cells (75, 76) . Apoptosis is physiologically more advantageous than necrosis, because the apoptotic cells are removed by phagocytosis and subsequent intracellular degradation, and thus preventing induction of inflammatory response and damage of surrounding tissue. Under normal conditions, the balance between apoptosis and cell survival is important in the development of multicellular organisms and in the regulation and maintenance of cell populations in tissues.
In fact, dysfunction of the apoptotic program is implicated in a variety of pathological conditions. Thus, defects in apoptosis can result in cancer, autoimmune diseases and spread of viral infections, while neurodegenerative disorders and ischemic diseases are caused or enhanced by excessive apoptosis (76, 77) .
The mechanisms of apoptosis are not fully understood, but numerous studies indicate the caspase cascade as a main key regulator of programmed cell death (78) . Caspases are cysteine-containing, aspartic acid-specific proteases, which exist as zymogens in the cytoplasm, mitochondrial intermembrane space and nuclear matrix of almost all cells. The mammalian caspase family contains at least 14 members that are divided in two groups: initiator caspases and executioner caspases (79) . The activation of caspases is due to apoptotic signals (such as ROS) and is associated with proteolytic cleavage of their N-terminal pro-domains, resulting in generation of small p10 and large p20 active subunits and formation of active p10/p20 tetramers (79) . There are three alternative pathways for caspase activation. The two commonly accepted mechanisms for caspase activation and induction of apoptosis are: 1) intrinsic mitochondrial-mediated pathway; and 2) extrinsic Fas-mediated pathway ( Figure 2) . The third less wellknown pathway for induction of apoptosis is the intrinsic endoplasmic reticulum-mediated pathway (77) .
Extrinsic pathway for induction of apoptosis
The extrinsic pathway of apoptosis is mediated by death receptors. Ligand-receptor interaction initiates proteinprotein interactions on cell membrane, which activates an initiator of caspases. The best known death receptors are Fas, TNF receptor type 1 (TNFR1), and receptors for TNF-related apoptosis-inducing ligand (TRAIL) type 1 and type 2 (80) . The death receptors are composed of three functional extracellular domains -ligandbinding, transmembrane, and intracellular ( Figure 2) . The ligands, which activate death receptors, belong to the TNF superfamily of cytokines (81) . Apoptotic signaling is initiated when the ligand binds to the death-receptor to form whole ligand-receptor-adaptor protein complex as the death-inducing signaling complex (DISC). Then, DISC initiates the assembly and activation of pro-caspase-8. The activated form of the enzyme (caspase-8) initiates apoptosis by cleaving other downstream caspases or executioner caspases (79) .
Recent studies suggest that ROS could be a direct activator of the death receptor and apoptotic induction through formation of lipid-raft-derived signaling platforms, but the mechanism remains to be defined.
Intrinsic mitochondrial pathway for induction of apoptosis
Intrinsic pathway is initiated within the cells. Internal stimuli, such as intracellular ROS, mitochondrial DNA damage, hypoxia and extremely high concentration of cytosolic calcium ions, are triggers of the mitochondrial pathway (82) . Regardless of the stimuli, this pathway is a result of increased permeability of mitochondrial membrane and release of pro-apoptotic molecules (as cytochrome c) from the intermembrane space of mitochondria into the cytosol (83, 84) . Cytochrome c is a water-soluble heme-containing protein, binding to the outer leaflet of the mitochondrial inner membrane through interactions with the anionic phospholipid cardiolipin. Normally, cytochrome c participates in the transfer of electrons between complex III and complex IV of the mitochondrial electron-transport chain (68, 85) . During mitochondrial dysfunction, which is characterized by overproduction of ROS, the tightly bound cytochrome c exhibits increased peroxidase activity, oxidizes cardiolipin and facilitates its detachment (85) (86) (87) . The oxidized cardiolipin is distributed to the outer part of the mitochondrial membrane and functions as a dock-platform for tBid (a membrane-targeted death ligand), which increases permeability of mitochondrial membrane and facilitates the movement of cytochrome c into the cytosol (88) . Therefore, the level of cardiolipin oxidation could be an important determinant of apoptotic susceptibility of the cells, but this possibility has to be proved. It is interesting that the redox-state of cytochrome c has been implicated in mitochondrial apoptotic signaling -cytochrome c is capable to activate caspases only when it is oxidized (89, 90) . In the cytosol, the release of cytochrome c can activate caspase-9, which in turn cleaves and activates executioner caspase-3. Then, some specific substances for caspase-3 [such as poly (ADP-ribose) polymerase (PARP)] could lead to apoptosis (91, 92) .
The intrinsic mitochondrial pathway is regulated by proteins belonging to the B-cell lymphoma 2 (Bcl-2) family, which participate in the construction of the outer mitochondrial membrane and determine its permeability (93) . There are two main groups of Bcl-2 proteins: 1) proapoptotic proteins (e.g., Bax, Bak, Bad, Bid, Bik, Bim) and 2) anti-apoptotic (e.g., Bcl-2, Bcl-w, Bfl-1, Bcl-xl). The anti-apoptotic proteins regulate apoptosis by blocking the mitochondrial release of cytochrome c, but the proapoptotic proteins act by promoting such release. It is hypothesized that the balance between pro-and antiapoptotic proteins determines whether apoptosis would be initiated or not (93) .
Many studies suggest that ROS can directly increase mitochondrial permeability and provoke depolarization of mitochondrial membrane with complete loss of mitochondrial potential (63) (64) (65) 83, 85) . For example, the components of the mitochondrial permeability transition pores [e.g., voltage-dependent ion channels (VDAC), adenine nucleotide translocase (ANT), cyclophilin D (cypD)] are targets of ROS and their oxidative modifications affect significantly the mitochondrial fluxes (62, 94, 95) . The increased hyperpolarization of mitochondrial membrane after treatment with hydrogen peroxide initiates a collapse of the mitochondrial membrane potential and translocation of mitochondrial pro-apoptotic proteins (Bax and Bad) and cytochrome c release (62, 65, 67, 82, 84, 85, 88, (94) (95) (96) .
The opening of permeability transition pores (PTPs) is considered as main event, which leads to mitochondrial depolarization and release of apoptotic factors (80) . PTPs are considered as a multi-protein complex, although their exact composition is still matter of debate. Under physiological conditions, the pores allow proper passage of small molecules "in" and "out" of the mitochondria. Under apoptotic stimuli, the opening of pores may lead to the loss of cytochrome c, malfunction of the electron-transport chain and depletion of adenosine triphosphate (ATP). The outflow of apoptotic factors can trigger cell death processes. Depending on the strength and duration of the apoptotic signal, the mitochondria may either exhibit transient (reversible) alteration in transmembrane potential, or reach a "point of no return" with a massive opening of the PTPs, collapse of membrane integrity and release of apoptotic factors (80).
Induction of oxidative stress by conventional chemotherapeutics -positive or negative approach in cancer therapy
There are many conclusive evidences which have shown that conventional anticancer drugs such as anthracyclines, widely used to treat various malignant tumors, are generators of ROS, inductors of oxidative stress and initiators of apoptosis in the cells (Figure 3) (20, (66) (67) (68) (69) (70) (71) (72) (73) (74) . For example, the anticancer activity of one of the most effective anthracycline antibiotics -doxorubicin, is due to the induction of DNA-damage, mainly through inhibition of DNA topoisomerase II enzyme after induction of double-strand DNA breaks (29) . It has been found that doxorubicin is localized into the mitochondria and is involved in biochemical reactions with production of ROS and other products of free-radical oxidation, which could induce mitochondrial swelling, ultrastructural changes and mitochondrial dysfunction. Doxorubicin-induced oxidative stress causes depolarization of the mitochondrial membrane and induction of apoptosis (71, 97) . Mizutani et al. have reported that doxorubicin triggers directly a production of hydrogen peroxide and induces apoptosis in human promyelocytic leukemia cell line HL-60 (66) . The authors have concluded that doxorubicin-induced overproduction of hydrogen peroxide and oxidative DNA damage are the most crucial apoptotic triggers, although doxorubicin-induced apoptosis may also involve topoisomerase II inhibition (66). Tsang et al. have reported that doxorubicin increases the intracellular hydrogen peroxide, followed by mitochondrial membrane depolarization, cytochrome c release and caspase-3 activation prior to DNA laddering in p53-null human osteosarcoma Saos-2 cells (67). These processes are accompanied by up-regulation of pro-apoptotic protein Bax and down-regulation of anti-apoptotic protein Bcl-2. The authors have also established that the catalase suppresses doxorubicin-induced apoptosis by abolishing of Bax upregulation without affecting Bcl-2 down-regulation (67) . The results from this study suggest that ROS and particularly hydrogen peroxide may act as a signal molecule for doxorubicin-induced cell death even in the absence of p53 tumor suppressor protein.
Bleomycin, also a widely used anticancer drug (conventional) for treatment of lymphomas, squamous cell carcinomas and testicular tumors, causes single-and double-strand breaks in DNA in vivo and in vitro, which results in cell damage (72, (98) (99) (100) . The mechanism of the antineoplastic effect of bleomycin involves the formation of bleomycin-iron complex, which can reduce molecular oxygen to superoxide and hydroxyl radicals that can attack DNA and trigger its cleavage (72) . Wallach-Dayan et al. have reported that bleomycin increases ROS in mouse lung epithelial (MLE) cells, which is accompanied by mitochondrial leakage, caspase-8 and caspase-9 activation, up-regulation of apoptotic (tumor necrotic) factor Fas, and induction of apoptosis (99) . Glutathione inhibits these effects, which suggests their dependence on ROS and particularly on hydrogen peroxide. In the study conducted by Cort et al., human testicular cancer cells are incubated with bleomycin or hydrogen peroxide for 72 h (100). The authors have observed that both substances induce apoptosis by enhancement of the caspase activity, release of cytochrome c into the cytosol, increase of Bax level and decrease of Bcl-2 level.
Cisplatin is another widely used anticancer drug, generally recognized as DNA-damaging agent (101) . It interacts predominantly with nucleophilic N7-sites of purine bases of DNA, leading to formation of DNA-protein and DNA-DNA inter-strand and intra-strand cross-links (102) . It has been shown that cisplatin induces production of ROS, as well as interacts with mitochondrial DNA (101, 103) . HarhajiTrajkovic et al. have reported that cisplatin increases ROS level and causes caspase activation and DNA fragmentation in U251 glioma, C6 glioma and L929 fibrosarcoma cell lines (102). Bragodo et al. have established on HCT116 colon carcinoma-derived cells that the apoptotic activity of cisplatin requires the onset of a p53-mediated p38α MAPK-pathway through generation of ROS (104) . All these studies suggest ROS-mediated induction of apoptosis by cisplatin, but do not specify which types of ROS are responsible for this process.
Some of the most effective chemotherapeutics, which are used for treatment of variety of malignancies, have shown toxic side effects on non-cancer tissues. For example, the side effects of doxorubicin are attributed to chronic toxic effects in the heart as cardiomyopathy and congestive heart failure (29, (69) (70) (71) 97) , those of bleomycin are associated with induction of pulmonary fibrosis (72, 99) , and those of cisplatin are kidney damages, gastrointestinal dysfunction and neuropathy (73, 103) . The side effects of conventional anticancer drugs could be also due to intracellular chelation of transition metals (e.g., iron and/or cupper ions) and triggering of Fenton-type reactions with subsequent production of the highly reactive hydroxyl radicals (19, 105, 106) . All studies mentioned above, as well as many other studies consider that the efficiency of the conventional anticancer drugs is due to induction of oxidative stress in the cancer cells, but they also suggest that this is a reason for their toxic side effects on non-cancer cell and tissues due to induction of redox-imbalance in whole organism (30, 66, 67, (69) (70) (71) (72) (73) (74) (97) (98) (99) 103, 106, 107) .
Currently, it is not clear whether the mechanisms for induction of ROS by conventional anticancer drugs are the same in cancer and non-cancer cells or they are different. It is generally accepted that the accumulation of genetic alterations and mutations in cancer cells are the main triggers of ROS. In non-cancer cells, the mechanisms might be different, e.g., by induction of endoplasmic reticulum stress and subsequent production of ROS (108) (109) (110) (111) . Thus, the efforts of scientists are directed to achieve therapeutic selectivity and prevent side effects and drug resistance by altering the unique biochemical pathways that distinguish the cancer cells from normal ones and to design new therapeutic strategies based on their different redoxhomeostasis (19, 110) . It raises several questions: 1) Is it possible to develop therapeutic approach, accompanied by induction of apoptosis in cancer cells without changes in the redox-homeostasis of the normal cells? 2) Is it possible to induce apoptosis in cancer cells by ROS-independent mechanisms? 3) Which is better to increase or decrease ROS in cancer cells?
Is it obligatory to raise ROS level to induce apoptosis in cancer cells?
ROS as a consequence (side effect) of apoptosis
It is still disputable whether the ROS are a reason for induction of apoptosis or are they a side effect induced by the mechanism of cell death. The initial idea for the role of ROS in apoptosis was based on the observation that Bcl-2 has an apparent antioxidant function in mammalian cells (111) . Experimental data have shown that overexpression of Bcl-2 protects cells from lipid peroxidation and thiol oxidation, induced by menadione and hydrogen peroxide (111) (112) (113) . Bcl-2 also protects cells from apoptosis at limited production of ROS. For example, Cai et al. have used staurosporine-treated HL-60 cells to study the mechanism of generation of ROS during apoptosis (111) . The authors try to clarify whether the oxidation signals in the cells precede or follow the release of cytochrome c into the cytosol and initiation of apoptosis. They measure the dynamic of the redox-state of intracellular glutathione as a function of the incubation time with staurosporine (an inductor of apoptosis). The results have demonstrated a release of cytochrome c from mitochondria into the cytosol after 1-hour incubation with staurosporine, while the oxidation of intracellular glutathione begins after 2-hours incubation (111) . Usually antioxidants, such as N-acetylcysteine, can inhibit apoptosis in cells, whose mechanism for induction of cell death depends on their redox-status (114) . However, the experiments of Cai et al. show that in staurosporine-induced apoptosis, the caspase activation seems to be redox-insensitive since the treated cells are not sensitive to N-acetyl-cysteine. These results are also confirmed by measurement of DNA fragmentation and phosphatidylserine translocation on the surface of cell membrane (111) .
In vitro data on cell-free systems have indicated that the caspase 3 activation is independent on the redox-state of cytochrome c and the activation of caspase 3 and caspase 9 could cause ROS production (111, 115) . Thus, when ROS is generated simultaneously with the direct activation of caspases, it might be only a side effect, which does not relate to the key signaling events leading to the caspase-dependent cell death (111) .
ROS-independent apoptosis
Recently, several studies have reported induction apoptosis by ROS-independent mechanism (116-120). Jacobson and Raff have shown that apoptosis has occurred when the cells are cultivated in hypoxic conditions without presence of ROS-generating substances, such as menadione or hydrogen peroxide (116) . In similar experiments, Shimizu et al. have failed to detect ROS during hypoxia-induced apoptosis (117) . These evidences suggest that ROS are not obligator effectors in the apoptosis. Ko et al. have also described ROS-independent cell death in HL-60 cells, induced by myricetin, a flavonoid with antioxidant properties (118) . In this study, the myricetin-inducing apoptosis is characterized by decrease of mitochondrial functions and Bcl-2/Bax ratio, translocation of cytochrome c from the mitochondria into the cytosol and activation of caspases 3 and 9 without significant induction of intracellular ROS. ROSindependent mechanism of apoptosis in myricetin-treated HL-60 cells has confirmed by using antioxidants such as N-acetyl-cysteine, catalase, SOD, and tiron. All antioxidants and antioxidant enzymes do not protect the myricitintreated cells (118) . Furthermore, the authors have observed that myricetin significantly decreases hydrogen peroxideinduced intracellular production of hydroperoxides (118).
Hou et al. have demonstrated ROS-independent cell death after treatment of HL-60 cells with gossypol, a polyphenolic compound existing in the seeds of cotton (119) . The level of ROS in gossypol-treated cells was similar to that in non-treated cells. Antioxidants, such as N-acetyl-cysteine and catalase, did not inhibit gossypol-induced caspase-3 activation, PARP degradation, and DNA fragmentation (119) . The gossypol-induced apoptosis was accompanied by cleavage of Bid protein, loss of mitochondrial potential, cytochrome c release into the cytosol, and activation of caspases 3, 8, and 9 (119) . Similar data have been reported by Lin et al. (120) . The authors have observed that rhein, an anthraquinone compound used in Chinese medicine, induces apoptosis in HL-60 cells by ROS-independent mechanism(s), because the antioxidants such as N-acetylcysteine, tiron and catalase did not suppress rhein-induced apoptosis (120) .
Combination between redox-modulators and anticancer drugs as a possible trigger of ROS-independent apoptosis in cancer cells
In the last two decades, many data have shown that natural or synthetic compounds, which modulate cellular redoxstatus, exhibit also anticancer effects (80, (121) (122) (123) (124) (125) (126) . Some of these redox-modulators could induce production of ROS, but in most cases their anticancer activity is connected to the influence of signaling pathways for regulation of physiological processes (e.g., pathways responsible for cell survival, proliferation, or apoptosis), rather than strong oxidative stress and damage of biomacromolecules. For example, the anticancer effect of 2-deoxy-D-glucose (2-DDG), an inhibitor of glycolysis, is connected with intracellular ATP depletion (127), disruption of thiol metabolism (128) (129) (130) , limited synthesis of NADPH (50% in comparison with non-treated cells) (131) and eventually induction of oxidative stress mainly in the cancer cells (112, 129, 131) .
Aykin-Burns et al. have studied the sensitivity of cancer cells and normal cells to glucose-deprivation-induced cytotoxicity (132) . The authors have measured the levels of superoxide and hydroperoxides inducing by treatment of both types of cells with 2-DDG. The results have shown that cancer cells are characterized by significantly increased levels of superoxide (2-20-fold) and hydroperoxides (1.8-10-fold), in comparison with the normal cells (132) .
In our recent study, we also found that 2-DDG sensitizes leukemia cells (Jurkat, derived from acute lymphoblastic leukemia) to new generation anticancer drugs, such as barasertib, bortezomib, everolimus, lonafarnib and palbociclib (132) . In the case of everolimus and barasertib, the combination with 2-DDG leads to a very strong synergistic cytotoxicity, accompanied by a strong induction of apoptosis, without increasing ROS level in the treated cells. In contrast, 2-DDG decreases doxorubicin-mediated generation of ROS and induction of apoptosis, which results in diminishing of the cytotoxicity of doxorubicin towards those cells. This study shows that combining newgeneration anticancer drugs with a redox-modulator (such as 2-DDG) markedly enhances the anticancer effect at a very low concentration of the drug.
Many in vitro and in vivo studies suggest that other redoxmodulator, docosahexaenoic acid (DHA: an essential fatty acid derived from fish oil), also has anticancer activity and can improve the efficiency of conventional cancer therapy: DHA suppresses tumor cell proliferation, reduces tumor growth in experimental animals, inhibits drug resistance in various cancer cell lines, and exerts cytotoxic effects on cancer cells, but it is significantly less cytotoxic for normal cells (133) (134) (135) (136) (137) (138) (139) (140) (141) (142) .
Some authors have observed that the combination of DHA with anticancer drugs induces apoptosis in cancer cells, which is accompanied by an enhancement of the level of ROS (143) (144) (145) , but others did not detect any changes in this parameter (146, 147) . For example, Lin et al. have found that DHA inhibits doxorubicin-induced generation of ROS and elevates the activity of catalase and SOD in NRK-52E cells, a rat renal proximal tubular cell line (147) . DHA sensitizes cancer cell lines A-172 and U-87 MG (derived from glioblastoma) and A-427 (derived from bronchial carcinoma) to doxorubicin (146) . In this case, DHA increases the level of ROS in doxorubicin-treated A-427 cells, but does not influence the level of ROS in A-172 and U-87 cells.
Currently, we described a synergistic cytotoxicity between DHA and anticancer drugs everolimus and barasertib, which is ROS-dependent, but specific for cancer cells (particularly for Jurkat) (148) . These combinations were harmless to normal lymphocytes and did not induce abnormal production of ROS in those cells. Our data suggest that DHA could be used as a supplementary component in the anticancer chemotherapy, which allows decreasing the therapeutic doses of everolimus and barasertib and minimizing their side effects. This assumption can also be made for other chemotherapeutics that show sinergistic cytotoxic effects in combination with DHA (e.g., palbociclib and lonafarnib).
Conclusions
The data described above suggest that in some cases using a redox-modulator, it is possible to influence the cellular redox-status in such a way in order to reduce the production of ROS, and to induce apoptosis in cancer cells by ROSindependent mechanisms. This could be a possible approach to minimize side effects of conventional cancer therapy on normal cells and tissues.
